Related Experiment Video

Updated: Jan 13, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.7K

Lipoprotein(a) and Aortic Valve Stenosis: From Pathophysiology to Emerging Pharmacological Agents

Federica Agnello1,2, Giulia Laterra1,2, Lorenzo Scalia2

  • 1Faculty of Medicine and Surgery, Università degli Studi di Enna "Kore", Piazza dell'Università, 94100 Enna, Italy.

Journal of Clinical Medicine
|January 10, 2026
PubMed

Insights

Lipoprotein(a) [Lp(a)] is a key factor in aortic valve stenosis (AVS) development. Lp(a)-lowering therapies show promise for managing this common heart condition.

Area of Science:

  • Cardiology
  • Biochemistry
  • Genetics

Background:

  • Aortic valve stenosis (AVS) is the most prevalent valvular heart disease globally.
  • Currently, no pharmacological treatments exist for AVS, necessitating novel therapeutic strategies.
  • Lipoprotein(a) [Lp(a)] is increasingly recognized as a significant risk factor in AVS pathogenesis.

Purpose of the Study:

  • To review the current understanding of Lp(a)'s role in AVS pathophysiology.
  • To evaluate the diagnostic and prognostic value of Lp(a) in AVS.
  • To explore the therapeutic potential of Lp(a)-lowering agents for AVS management.

Main Methods:

  • Literature review of existing studies on Lp(a) and AVS.
  • Analysis of evidence linking lipid metabolism, inflammation, and calcification in AVS.
  • Examination of emerging Lp(a)-targeted therapies.

Main Results:

  • Lp(a) plays a causal role in AVS by connecting lipid metabolism, inflammation, and valve calcification.
  • Lp(a) levels are genetically determined and stable, making them a viable therapeutic target.
  • Emerging therapies like antisense oligonucleotides and siRNA show potential for Lp(a) reduction.

Conclusions:

  • Lp(a) is a critical factor in AVS development and progression.
  • Targeting Lp(a) represents a promising new avenue for AVS pharmacological treatment.
  • Lp(a)-lowering agents could offer the first medical option to slow AVS progression in high-risk individuals.

Keywords:
Lp(a)PCSK9iaortic valve stenosisatherosclerosisstatin

More Related Videos

A Rabbit Aortic Valve Stenosis Model Induced by Direct Balloon Injury07:10

A Rabbit Aortic Valve Stenosis Model Induced by Direct Balloon Injury

Published on: March 31, 2023

1.5K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
868
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
385
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
301
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
359